Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
NEWARK, Calif., Nov. 13, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, the Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference, and the Global Mizuho Investor Conference.
| 29th Annual Piper Jaffray Healthcare Conference | ||||
| Date: | Wednesday, November 29 | |||
| Time: | 12:00pm Eastern time | |||
| Location: | Lotte New York Palace Hotel | |||
| Webcast: | http://ir.cymabay.com/events | |||
| Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference | |||||
| Date: | Thursday, November 30 | ||||
| Time: | 12:05pm Eastern Time | ||||
| Location: | Boston Harbor Hotel | ||||
| Webcast: | http://ir.cymabay.com/events | ||||
| Global Mizuho Investor Conference | |||
| Date: | Tuesday, December 5 | ||
| Time: | One-on-One Format | ||
| Location: | Lotte New York Palace Hotel | ||
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
